Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 2/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456724 | 0.93 | PDE1B (0.49) | MAPTTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL2774113 | 0.80 | AGTR1 (0.48) | MAPTTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL13070234 | 0.77 | AGTR1 (0.54) | MAPTTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL17483612 | 0.69 | PDE1B (0.76) | PDE1B | |
| SCHEMBL18808388 | 0.68 | PDE1B (0.52) | PDE1B | |
| SCHEMBL16637309 | 0.67 | HTT (0.52) | MAPTTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL2776910 | 0.66 | AGTR1 (0.54) | HDAC8HDAC6HDAC1HDAC11PDE1B | |
| SCHEMBL19611087 | 0.64 | ADORA2B (0.53) | HDAC8HDAC6HDAC1HDAC11ADORA2B | |
| SCHEMBL24031181 | 0.64 | THRB (0.71) | MAPTTP53HDAC8HDAC6HDAC1 | |
| SCHEMBL16643997 | 0.64 | ADORA2B (0.56) | MAPTTP53HDAC8HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253630-A1 | Heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |